07.10.2013 • NewsDiovanNovartispatent expiries

Novartis Overhauls Japanese Unit after Drug Scandal

Novartis  said it had overhauled management operations and sanctioned key staff in Japan after a scandal involving research into its Diovan blood pressure drug in the country.

The Swiss company's pharmaceutical head David Epstein said the episode would not have a significant impact on the group's profits, although he acknowledged sales of the drug had fallen.

"Overall Diovan is a relatively small part of our portfolio, given the breadth of the medicines that we have, so the impact should not be significant," Epstein said. Epstein told a news conference that oversight at its Japan unit had fallen short and, as a result, Novartis was setting up a compliance advisory panel to prevent future such problems.

"Clearly there should have been more control as well as better training in Japan," Epstein said. "Unfortunately that was not the case. Those controls are now in place so that this cannot happen again." He also acknowledged, in response to a reporter's question, that the company should have paid more attention to questions raised by some outside experts about the studies into Diovan.

A Japanese health ministry panel this week called for the ministry to investigate Novartis Pharma, the company's Japanese arm, saying it may have violated the law when it cited studies based on allegedly manipulated data.

Japan accounted for around a quarter of Diovan's global sales before the scandal and, overall, it made up 9 % of total group sales in 2012, or $5.36 billion. Diovan was once Novartis' top-selling product but its importance is declining and the patent on the medicine is due to expire in Japan this year.

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.